A Vickers

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Systematic reviews of complementary therapies - an annotated bibliography. Part 1: acupuncture
    K Linde
    Centre for Complementary Medicine Research, Department of Internal Medicine II, Technische Universitat, Munchen, Kaiserstr 9, 80801 München, Germany
    BMC Complement Altern Med 1:3. 2001
  2. pmc A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making
    Athanasios Tsalatsanis
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL, USA
    BMC Med Inform Decis Mak 10:51. 2010
  3. pmc Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 116:2612-20. 2010
  4. pmc Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients
    Barrie R Cassileth
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue at 74th Street, New York, NY 10021, USA
    Cancer Chemother Pharmacol 65:67-71. 2009
  5. pmc The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, NY 10021, USA
    Trials 10:14. 2009
  6. pmc Counseling the post-radical prostatectomy patients about functional recovery: high predictiveness of current status
    Andrew J Vickers
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Urology 84:158-63. 2014
  7. pmc Empirical study of data sharing by authors publishing in PLoS journals
    Caroline J Savage
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS ONE 4:e7078. 2009
  8. ncbi request reprint A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer
    Andrew J Vickers
    Department of Surgery, Memorial Sloane Kettering Cancer Center, New York, NY Department of Epidemiology and Biostatistics, Memorial Sloane Kettering Cancer Center, New York, NY Electronic address
    Urology 83:592-6. 2014
  9. pmc Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med 12:26. 2014
  10. pmc The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:3007-11. 2013

Research Grants

Detail Information

Publications152 found, 100 shown here

  1. pmc Systematic reviews of complementary therapies - an annotated bibliography. Part 1: acupuncture
    K Linde
    Centre for Complementary Medicine Research, Department of Internal Medicine II, Technische Universitat, Munchen, Kaiserstr 9, 80801 München, Germany
    BMC Complement Altern Med 1:3. 2001
    ..Information on conditions, interventions, methods, results and conclusions was extracted using a pretested form and summarized descriptively...
  2. pmc A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making
    Athanasios Tsalatsanis
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL, USA
    BMC Med Inform Decis Mak 10:51. 2010
    ..We use the cognitive emotion of regret to serve as a link between systems 1 and 2 and to reformulate DCA...
  3. pmc Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 116:2612-20. 2010
    ..However, the association between PSA and cancer probably depends on a man's recent screening history...
  4. pmc Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients
    Barrie R Cassileth
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue at 74th Street, New York, NY 10021, USA
    Cancer Chemother Pharmacol 65:67-71. 2009
    ..To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC...
  5. pmc The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, NY 10021, USA
    Trials 10:14. 2009
    ..Unfortunately, contemporary randomized trials have become increasingly expensive, complex and burdened by regulation, so much so that many trials are of doubtful feasibility...
  6. pmc Counseling the post-radical prostatectomy patients about functional recovery: high predictiveness of current status
    Andrew J Vickers
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Urology 84:158-63. 2014
    ..To develop prediction models to help counsel post-radical prostatectomy patients about functional recovery...
  7. pmc Empirical study of data sharing by authors publishing in PLoS journals
    Caroline J Savage
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS ONE 4:e7078. 2009
    ..These policies are explicit, but remain largely untested. We sought to determine how well authors comply with such policies by requesting data from authors who had published in one of two journals with clear data sharing policies...
  8. ncbi request reprint A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer
    Andrew J Vickers
    Department of Surgery, Memorial Sloane Kettering Cancer Center, New York, NY Department of Epidemiology and Biostatistics, Memorial Sloane Kettering Cancer Center, New York, NY Electronic address
    Urology 83:592-6. 2014
    ....
  9. pmc Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med 12:26. 2014
    ..We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen (PSA) testing by age and baseline PSA...
  10. pmc The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:3007-11. 2013
    ....
  11. pmc A simple decision analytic solution to the comparison of two binary diagnostic tests
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 32:1865-76. 2013
    ..The methodology is easily extended to incorporate combinations of tests and the risk or side effects of a test...
  12. pmc Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 11:286-90. 2013
    ..However, the literature clearly shows that simplistic application of PSA velocity cutoffs is not of value for early detection of prostate cancer...
  13. pmc Responses to the Acupuncture Trialists' Collaboration individual patient data meta-analysis
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer, 307 East 63rd Street, 2nd Floor, New York, NY 10065, USA
    Acupunct Med 31:98-100. 2013
    ....
  14. pmc Acupuncture for chronic pain: individual patient data meta-analysis
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Intern Med 172:1444-53. 2012
    ..We aimed to determine the effect size of acupuncture for 4 chronic pain conditions: back and neck pain, osteoarthritis, chronic headache, and shoulder pain...
  15. pmc Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 119:143-9. 2013
    ..Data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were used and simple decision analytic techniques were applied to compare different eligibility criteria for a screening trial...
  16. pmc Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial
    Andrew Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 62:204-9. 2012
    ..Although there is randomized evidence that radical prostatectomy improves survival, there are few data on how benefit varies by baseline risk...
  17. pmc Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents
    Caroline Bennette
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    BMC Med Res Methodol 12:21. 2012
    ....
  18. pmc Predicting prostate cancer many years before diagnosis: how and why?
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    World J Urol 30:131-5. 2012
    ..Men with the top 10% of PSAs at a young age (PSA ~1.5 ng/ml or higher below 50) are at particularly high risk and should be subject to intensive monitoring...
  19. pmc Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 11215, USA
    Trials 13:23. 2012
    ..We aimed to determine the feasibility of implementing such a trial for radical prostatectomy...
  20. pmc Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers
    Iain Hrynaszkiewicz
    BioMed Central, 236 Gray s Inn Road, London WC1X 8HL, UK
    Trials 11:9. 2010
    ..Basic advice on file preparation is provided along with procedural guidance on prospective and retrospective publication of raw data, with an emphasis on randomised controlled trials...
  21. pmc Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: a simulation study
    Angel M Cronin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
    BMC Med Res Methodol 8:75. 2008
    ..Data from such studies are subject to what has been termed "verification bias". We evaluated statistical methods for verification bias correction when there are few false negatives...
  22. pmc Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study
    David Ulmert
    Departments of Laboratory Medicine and Clinical Sciences in Malmö, Lund University, University Hospital UMAS, Malmo, Sweden
    BMC Med 6:6. 2008
    ..We aimed to determine whether this association holds for advanced cancers, defined as clinical stage T3 or higher, or skeletal metastasis at the time of the cancer diagnosis...
  23. pmc Systematic reviews of complementary therapies - an annotated bibliography. Part 2: herbal medicine
    K Linde
    Centre for Complementary Medicine Research, Department of Internal Medicine II, Technische Universitat, Munchen, Kaiserstr 9, 80801 München, Germany
    BMC Complement Altern Med 1:5. 2001
    ..Information on conditions, interventions, methods, results and conclusions was extracted using a pre-tested form and summarized descriptively...
  24. pmc Systematic reviews of complementary therapies - an annotated bibliography. Part 3: homeopathy
    K Linde
    Centre for Complementary Medicine Research, Department of Internal Medicine II, Technische Universitat, Munchen, Kaiserstr 9, 80801 München, Germany
    BMC Complement Altern Med 1:4. 2001
    ..Information on conditions, interventions, methods, results and conclusions was extracted using a pretested form and summarized descriptively...
  25. pmc Systematic review of statistical methods used in molecular marker studies in cancer
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Cancer 112:1862-8. 2008
    ..In the current study, the experimental designs and statistical methods used in contemporary molecular marker studies are reviewed, particularly with respect to whether these evaluated a marker's clinical value...
  26. pmc How to improve accrual to clinical trials of symptom control 2: design issues
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 5:61-4. 2007
    ..Patient burden can be reduced by limiting the number of hospital visits and avoiding excessive numbers of questionnaires...
  27. pmc Long-term health outcomes of a decision aid: data from a randomized trial of adjuvant! In women with localized breast cancer
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
    Med Decis Making 29:461-7. 2009
    ..Decision aids are known to affect treatment choices and may therefore affect patient survival. The authors aimed to model the effects of the Adjuvant! decision aid on expected survival in women with early stage breast cancer...
  28. ncbi request reprint The surgical learning curve for prostate cancer control after radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Natl Cancer Inst 99:1171-7. 2007
    ..We analyzed the surgical learning curve for prostate cancer recurrence after radical prostatectomy...
  29. pmc Basic introduction to research: how not to do research
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 6:82-5. 2008
    ..As such, it is doubly important that clinical research is conducted by those with appropriate training, statistical help, and institutional support...
  30. pmc How to measure quality of life in integrative oncology research
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 4:100-3. 2006
    ..In many cases, it is preferable to use specific symptoms, such as pain or fatigue, as opposed to more generic quality of life scales...
  31. pmc Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 27:398-403. 2009
    ..We aimed to assess the published evidence for the clinical utility of PSA dynamics in this population...
  32. pmc Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, New York, NY 10065, USA
    BMC Med Inform Decis Mak 8:53. 2008
    ..Most critically, decision curve analysis can be applied directly to a data set, and does not require the sort of external data on costs, benefits and preferences typically required by traditional decision analytic techniques...
  33. pmc Which botanicals or other unconventional anticancer agents should we take to clinical trial?
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 5:125-9. 2007
    ....
  34. pmc Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 53:960-6. 2008
    ..We previously demonstrated that there is a learning curve for open radical prostatectomy. We sought to determine whether the effects of the learning curve are modified by pathologic stage...
  35. pmc Against diagnosis
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Intern Med 149:200-3. 2008
    ..The authors compare and contrast the diagnostic and risk prediction approaches and attempt to identify the types of medical problem to which each is best suited...
  36. pmc A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, East 63rd Street, New York, NY 10021, USA
    BMC Med 6:19. 2008
    ..We set out to determine whether a multivariable model including four kallikrein forms (total, free, and intact PSA, and human kallikrein 2 (hK2)) could predict prostate biopsy outcome in previously unscreened men with elevated total PSA...
  37. pmc Living proof and the pseudoscience of alternative cancer treatments
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 6:37-40. 2008
    ..It also suggests that little progress has been made in the conventional treatment of myeloma. This is highly misleading and may lead to cancer patients rejecting effective treatments...
  38. pmc Multiple assessment in quality of life trials: how many questionnaires? How often should they be given?
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 4:135-8. 2006
    ..Decisions about the appropriate number of assessments to use can be based on statistical properties derived from simple formulae...
  39. pmc The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 10:475-80. 2009
    ..Here we aim to characterise the learning curve for laparoscopic radical prostatectomy...
  40. pmc Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:907-12. 2010
    ..We determined whether prostate specific antigen velocity could predict repeat biopsy results in men with persistently increased prostate specific antigen after initial negative biopsy...
  41. pmc Validation study of a web-based assessment of functional recovery after radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Health Outcomes Group Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Health Qual Life Outcomes 8:82. 2010
    ..Logistical problems associated with using paper questionnaire limit their use in the clinic. We have implemented a web-interface ("STAR") for patient-reported outcomes after radical prostatectomy...
  42. pmc The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 16:4374-81. 2010
    ..We hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study...
  43. pmc Data and programming code from the studies on the learning curve for radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, USA
    BMC Res Notes 3:234. 2010
    ..Data include markers of cancer severity (stage, grade and prostate-specific antigen level), cancer outcome, and surgeon variables such as training and experience...
  44. pmc Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center
    Andrew Vickers
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 59:317-22. 2011
    ..Data on urinary and erectile outcomes, however, are lacking...
  45. pmc One statistical test is sufficient for assessing new predictive markers
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 44, New York, NY 10065 USA
    BMC Med Res Methodol 11:13. 2011
    ..These two steps often lead to discordant conclusions...
  46. pmc An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 103:462-9. 2011
    ....
  47. pmc Screening for prostate cancer: early detection or overdetection?
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Annu Rev Med 63:161-70. 2012
    ..In current U.S. practice, however, many men who are screened are unlikely to benefit, most men found to have low-risk cancers are referred for unnecessary curative treatment, and much treatment is given at low-volume centers...
  48. pmc Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 128:1697-702. 2011
    ..Although our findings have no direct clinical implications, studies investigating biological variables as predictors of outcome after curative resection of cancer should consider the impact of surgeon-specific factors...
  49. pmc Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication
    Andrew Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:2493-8. 2010
    ..We aimed to replicate our findings in a large, independent, representative, population-based cohort...
  50. pmc A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 16:3232-9. 2010
    ..Although this model accurately predicts the result of biopsy in unscreened men, its properties for men with a history of PSA screening have not been fully characterized...
  51. pmc Phase II designs for anticancer botanicals and supplements
    Andrew J Vickers
    Department of Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 7:35-40. 2009
    ..Such a design asks whether patients treated by the new agent are doing better than expected; if so, this suggests that the agent should be tested further in phase III trials...
  52. pmc Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 307 E 63rd St, New York, NY 10021, USA
    Eur Urol 56:753-60. 2009
    ..It has been suggested that changes in prostate-specific antigen (PSA) over time (ie, PSA velocity [PSAV]) aid prostate cancer detection. Some guidelines do incorporate PSAV cut points as an indication for biopsy...
  53. pmc Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach
    Andrew J Vickers
    Department of Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 115:5460-9. 2009
    ....
  54. pmc Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10021, USA
    J Clin Oncol 28:1112-6. 2010
    ..Clinicians who believe that it is unnecessary to prevent all cancers, but that preventing those readily detectable by screening would be desirable, would be best off recommending finasteride only to a high-risk subgroup...
  55. pmc The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point
    Andrew Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 183:1360-5. 2010
    ..Surgical margin status is commonly used as an end point for surgical learning. We examined the surgical margin learning curve and investigated whether surgical margins are a good marker for oncological outcome...
  56. pmc Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Oncol 37:31-8. 2010
    ..Such decision analytic techniques hold the promise of determining whether clinical implementation of prediction models would do more good than harm...
  57. pmc How do you tell whether a change in surgical technique leads to a change in outcome?
    Andrew J Vickers
    Department of Epidemiology and Biostatistics and Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:1510-4. 2010
    ..Simple comparison of results before and after surgical modification may be confounded by the surgical learning curve. We developed a statistical method applicable to analyzing before/after surgical studies...
  58. pmc Individual patient data meta-analysis of acupuncture for chronic pain: protocol of the Acupuncture Trialists' Collaboration
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Trials 11:90. 2010
    ..The Acupuncture Trialists' Collaboration, a group of trialists, statisticians and other researchers, was established to synthesize patient-level data from several recently published large, high-quality trials...
  59. pmc How to improve accrual to clinical trials of symptom control 1: recruitment strategies
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 5:38-42. 2007
    ..The information given to patients during any initial contact should be as simple and general as possible: presenting too much information too soon can be overwhelming and off-putting...
  60. ncbi request reprint Interpreting data from randomized trials: the Scandinavian prostatectomy study illustrates two common errors
    Andrew Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 2:404-5. 2005
  61. pmc Statistical considerations for use of composite health-related quality-of-life scores in randomized trials
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Qual Life Res 13:717-23. 2004
    ..There may be several clinically and scientifically reasonable alternative combinations of subscales for the primary outcome measure...
  62. ncbi request reprint Why use placebos in clinical trials? A narrative review of the methodological literature
    A J Vickers
    Integrative Medicine Service and Biostatistics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 11215, USA
    J Clin Epidemiol 53:157-61. 2000
    ..Placebo-controlled trials have high internal validity but may be difficult to apply to clinical practice; the situation is reversed for trials without placebo control...
  63. ncbi request reprint Statistical reanalysis of four recent randomized trials of acupuncture for pain using analysis of covariance
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin J Pain 20:319-23. 2004
    ..Each trial used statistical methods that did not adjust for baseline pain scores and were thus of suboptimal power. The objective of this study is to reanalyze the trials using analysis of covariance (ANCOVA)...
  64. ncbi request reprint Analysis of variance is easily misapplied in the analysis of randomized trials: a critique and discussion of alternative statistical approaches
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Department of Medicine, MSKCC, New York, NY 10021, USA
    Psychosom Med 67:652-5. 2005
    ..Given that ANOVA is easily misapplied in the analysis of randomized trials, alternative approaches such as regression methods should be considered in preference...
  65. pmc Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, Howard 1312a, New York, NY 10021, USA
    BMC Med Res Methodol 5:35. 2005
    ....
  66. pmc Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence?
    Andrew J Vickers
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:576-80. 2006
    ..In the current study, the authors evaluated whether time from biopsy to radical prostatectomy (RP) was predictive of postoperative biochemical disease recurrence (BCR)...
  67. pmc Decision curve analysis: a novel method for evaluating prediction models
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
    Med Decis Making 26:565-74. 2006
    ....
  68. pmc How to randomize
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 4:194-8. 2006
    ..Computer randomization can easily incorporate extensions of randomization, such as blocking, stratification, and minimization, which can help ensure balance between groups...
  69. pmc Unconventional anticancer agents: a systematic review of clinical trials
    Andrew J Vickers
    Integrative Medicine Service and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:136-40. 2006
    ..The objective of this study was to review systematically the methodologies applied in clinical trials of unconventional treatments specifically for cancer...
  70. pmc How to design a phase I trial of an anticancer botanical
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 4:46-51. 2006
    ..Increasing the use of phase I methodology would ensure a more systematic development of botanicals as anticancer agents. This would likely increase the chance that at least one such agent would be proven to extend lives...
  71. ncbi request reprint Acupuncture for postchemotherapy fatigue: a phase II study
    Andrew J Vickers
    Intergrative Medicine Service, and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1731-5. 2004
    ..To determine whether improvement in postchemotherapy fatigue following acupuncture treatment is substantial enough to warrant a controlled trial...
  72. pmc Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, NY 10021, USA
    BMJ 328:744. 2004
    ..To determine the effects of a policy of "use acupuncture" on headache, health status, days off sick, and use of resources in patients with chronic headache compared with a policy of "avoid acupuncture."..
  73. ncbi request reprint How to reduce the number of patients needed for randomized trials: a basic introduction
    A Vickers
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Complement Ther Med 9:234-6. 2001
    ..There are considerable economic and ethical advantages to reducing sample size by a third; however, ANCOVA is statistically complex and expert statistical help is required...
  74. pmc The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study
    A J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue New York, New York 10021, USA
    BMC Med Res Methodol 1:6. 2001
    ..The statistical power of each method was determined for a hypothetical randomized trial under a range of correlations between baseline and post-treatment scores...
  75. ncbi request reprint Unconventional therapies for cancer and cancer-related symptoms
    A J Vickers
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 2:226-32. 2001
    ..Such complementary therapies are increasingly provided at mainstream cancer centres...
  76. pmc Message to complementary and alternative medicine: evidence is a better friend than power
    A J Vickers
    Integrative Medicine, Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, USA
    BMC Complement Altern Med 1:1. 2001
    ..A significant constituency within CAM, however, appears to have substantive doubts about EBM and some are expressly hostile...
  77. ncbi request reprint Homoeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes
    A J Vickers
    Memorial Sloan Kettering Cancer Center, Integrative Medicine Service, 1275 York Avenue, New York, NY 10021, USA
    Cochrane Database Syst Rev 3:CD001957. 2006
    ..The rationale for its use in influenza comes from the homoeopathic principle of 'let like be cured by like'. This medicine is manufactured from wild duck heart and liver, which are said to be reservoirs for influenza viruses...
  78. ncbi request reprint Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials
    Andrew Vickers
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Invest 20:1069-79. 2002
    ..Phase I and II methodology is also problematic: botanicals have low toxicity and are unlikely to cause rapid tumor regression. There is currently minimal regulation of botanical medicines...
  79. pmc How many repeated measures in repeated measures designs? Statistical issues for comparative trials
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, Howard 13, 1275 York Avenue NY, NY 10021, USA
    BMC Med Res Methodol 3:22. 2003
    ..There has been little guidance in the literature as to selecting the optimal number of repeated measures...
  80. ncbi request reprint Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Control Clin Trials 24:731-5. 2003
    ..Further research might usefully examine the value of global assessment for imputation of missing data in a variety of different settings...
  81. ncbi request reprint Underpowering in randomized trials reporting a sample size calculation
    Andrew J Vickers
    Integrative Medicine Service, Biostatistics Service, Memorial Sloan Kettering Cancer Center, Howard 1312a, 1275 York Avenue, NY 10021, USA
    J Clin Epidemiol 56:717-20. 2003
    ..The objective of this study was to determine whether standard deviations (SDs) used in sample size calculations are smaller than those found in the resulting study sample, thereby leading to underpowered studies...
  82. pmc Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:972-6. 2007
    ..We sought to determine the proportion of phase II trials that require historical data to establish the null and to determine how these historical estimates were derived...
  83. pmc A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
    Amine Benchikh
    Hopital Bichat Claude Bernard, Paris, France
    BMC Cancer 10:635. 2010
    ..Here we investigate the properties of our panel in men subject to clinical work-up before biopsy...
  84. pmc Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy
    Karim Touijer
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 49:853-8. 2006
    ..We sought to determine the impact of a process of continuous control and monitoring on the positive surgical margin rate in a contemporary series of laparoscopic radical prostatectomy...
  85. ncbi request reprint Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy
    Karim Touijer
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 52:1090-6. 2007
    ..To prospectively compare in a contemporary and contemporaneous series the positive surgical margin (PSM) rate between laparoscopic (LRP) and retropubic (RRP) radical prostatectomy at the same institution...
  86. ncbi request reprint Alternative medicine use worldwide: the International Union Against Cancer survey
    B R Cassileth
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 91:1390-3. 2001
    ..In the current study, the authors attempted to surmount the deficiencies of previous surveys and elicit information regarding the use of alternative treatments of cancer worldwide...
  87. ncbi request reprint Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 176:100-3; discussion 103-4. 2006
    ..We evaluated patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumors to determine predictors of teratomatous elements in the retroperitoneum...
  88. ncbi request reprint Acupuncture: integration into cancer care
    Gary Deng
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Soc Integr Oncol 4:86-92. 2006
    ..Acupuncture is useful complementary therapy in cancer care. Its integration into regular oncology practice can improve the supportive care of cancer patients...
  89. pmc Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:1508-13. 2010
    ..We assessed the effect of radical prostatectomy (RP) and external beam radiotherapy (EBRT) on distant metastases (DM) rates in patients with localized prostate cancer treated with RP or EBRT at a single specialized cancer center...
  90. ncbi request reprint Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 119:152-6. 2006
    ..Similarly, the STX transcript level of posttreatment marrows was also highly prognostic of outcome (PFS, p = 0.001; OS, p < 0.0005). We conclude that STX mRNA has potential clinical utility as a molecular marker of metastatic NB...
  91. pmc Complications after radical and partial nephrectomy as a function of age
    William T Lowrance
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:1725-30. 2010
    ..We determined if the association of age and perioperative outcomes differed between nephrectomy types...
  92. ncbi request reprint Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Leuk Res 29:679-83. 2005
    ..No clinical toxicity was observed. The therapeutic efficacy and lack of toxicity of this combination supports further investigation into its clinical utility...
  93. ncbi request reprint Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 51:557-64. 2002
    ..Given the favorable efficacy and toxicity profile of oral beta- D-glucan treatment, the role of natural products that contain beta-glucan in cancer treatment as an enhancer of the effect of mAb therapy deserves further study...

Research Grants2

  1. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  2. Clinically-Integrated Randomized Trial of Radical Prostatectomy
    Andrew Vickers; Fiscal Year: 2008
    ..We intend to pilot this methodology in a trial comparing modifications to radical prostatectomy. ..